PARP1 and cancer: Furthermore, despite the notable effort invested in clinical trials of combinatorial therapeutic strategies involving PARP inhibitors and other agents targeting proteins in DNA-damage response pathways across many cancer types34, this approach is frequently limited by overlapping toxicities of the agents used in combination with PARP inhibitors56.